HK1096293A1 - Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker - Google Patents
Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blockerInfo
- Publication number
- HK1096293A1 HK1096293A1 HK07103420.7A HK07103420A HK1096293A1 HK 1096293 A1 HK1096293 A1 HK 1096293A1 HK 07103420 A HK07103420 A HK 07103420A HK 1096293 A1 HK1096293 A1 HK 1096293A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- angiotensin
- selective
- pharmaceutical composition
- receptor
- imidazoline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03103763 | 2003-10-10 | ||
PCT/EP2004/052468 WO2005039639A2 (en) | 2003-10-10 | 2004-10-07 | Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1096293A1 true HK1096293A1 (en) | 2007-06-01 |
Family
ID=34486329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07103420.7A HK1096293A1 (en) | 2003-10-10 | 2007-03-30 | Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker |
Country Status (20)
Country | Link |
---|---|
US (2) | US20050143435A1 (xx) |
EP (1) | EP1673107B1 (xx) |
JP (1) | JP4829115B2 (xx) |
KR (1) | KR101137084B1 (xx) |
CN (1) | CN100453117C (xx) |
AT (1) | ATE390148T1 (xx) |
AU (1) | AU2004283047B2 (xx) |
BR (1) | BRPI0415198A (xx) |
CA (1) | CA2541867C (xx) |
DE (1) | DE602004012763T2 (xx) |
ES (1) | ES2304624T3 (xx) |
HK (1) | HK1096293A1 (xx) |
IL (1) | IL174762A (xx) |
MX (1) | MXPA06004029A (xx) |
NO (1) | NO335735B1 (xx) |
PL (1) | PL1673107T3 (xx) |
RU (1) | RU2362561C2 (xx) |
UA (1) | UA83077C2 (xx) |
WO (1) | WO2005039639A2 (xx) |
ZA (1) | ZA200601804B (xx) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4675586B2 (ja) * | 2004-06-23 | 2011-04-27 | 壽製薬株式会社 | 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤 |
CA2625646A1 (en) * | 2005-10-25 | 2007-05-03 | Merck & Co., Inc. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
DE602007012692D1 (de) | 2006-06-16 | 2011-04-07 | Lek Pharmaceuticals | Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan |
ATE497799T1 (de) | 2007-07-25 | 2011-02-15 | Schott Forma Vitrum Ag | Verabreichungsvorrichtung |
EP2203158A4 (en) * | 2007-10-30 | 2012-12-26 | Reddys Lab Ltd Dr | PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE |
UA103688C2 (uk) * | 2009-06-30 | 2013-11-11 | Санофі | Тверді фармацевтичні композиції з фіксованою дозою, що містять ірбесартан і амлодипін, їх отримання і їх терапевтичне застосування |
CN102850331B (zh) * | 2012-09-17 | 2015-05-20 | 符爱清 | 一种化合物的制备方法 |
MD4412C1 (ro) * | 2014-08-29 | 2016-11-30 | Алёна ДУРНЯ | Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă |
PL424452A1 (pl) * | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu |
RU2734281C1 (ru) * | 2019-06-11 | 2020-10-14 | Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) | Композиция для лечения артериальной гипертензии и ассоциированных с ней патологий сердечно-сосудистой системы |
WO2020257736A1 (en) * | 2019-06-21 | 2020-12-24 | The Broad Institute, Inc. | Agents for reversing toxic proteinopathies |
GB202006074D0 (en) * | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
US5354867A (en) * | 1988-12-06 | 1994-10-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
US5312828A (en) * | 1989-06-14 | 1994-05-17 | Finkelstein Joseph A | Substituted imidazoles having angiotensin II receptor blocking activity |
US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
DE59107440D1 (de) * | 1990-02-19 | 1996-04-04 | Ciba Geigy Ag | Acylverbindungen |
US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
JP2707390B2 (ja) * | 1992-05-22 | 1998-01-28 | 壽製薬株式会社 | シクロヘプトイミダゾ−ル誘導体及びその製造方法並びにこれを含有する薬剤 |
DE4423177A1 (de) * | 1994-07-01 | 1996-01-04 | Kali Chemie Pharma Gmbh | Antihyperglykämisch wirksame Arzneimittel |
US5972948A (en) * | 1994-07-01 | 1999-10-26 | Solvay Pharmaceuticals Gmbh | Method of inhibiting hyperglycemia and pharmaceutical composition for use therein |
NO980546L (no) * | 1997-02-11 | 1998-08-12 | Lilly Co Eli | Farmas°ytiske midler |
US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
JP4107831B2 (ja) * | 2000-11-21 | 2008-06-25 | 第一三共株式会社 | 医薬組成物 |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
HU0200980D0 (xx) * | 2002-03-14 | 2002-05-29 | Gabor S Pal Dr | |
AU2003268493A1 (en) * | 2002-09-11 | 2004-04-30 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
-
2004
- 2004-10-07 JP JP2006530280A patent/JP4829115B2/ja not_active Expired - Fee Related
- 2004-10-07 KR KR1020067006561A patent/KR101137084B1/ko not_active IP Right Cessation
- 2004-10-07 EP EP04766880A patent/EP1673107B1/en active Active
- 2004-10-07 US US10/959,317 patent/US20050143435A1/en not_active Abandoned
- 2004-10-07 MX MXPA06004029A patent/MXPA06004029A/es active IP Right Grant
- 2004-10-07 UA UAA200604846A patent/UA83077C2/ru unknown
- 2004-10-07 AT AT04766880T patent/ATE390148T1/de not_active IP Right Cessation
- 2004-10-07 BR BRPI0415198-4A patent/BRPI0415198A/pt not_active Application Discontinuation
- 2004-10-07 CA CA2541867A patent/CA2541867C/en not_active Expired - Fee Related
- 2004-10-07 ZA ZA200601804A patent/ZA200601804B/en unknown
- 2004-10-07 DE DE602004012763T patent/DE602004012763T2/de active Active
- 2004-10-07 WO PCT/EP2004/052468 patent/WO2005039639A2/en active IP Right Grant
- 2004-10-07 RU RU2006115796/15A patent/RU2362561C2/ru active
- 2004-10-07 ES ES04766880T patent/ES2304624T3/es active Active
- 2004-10-07 CN CNB2004800285299A patent/CN100453117C/zh not_active Expired - Fee Related
- 2004-10-07 PL PL04766880T patent/PL1673107T3/pl unknown
- 2004-10-07 AU AU2004283047A patent/AU2004283047B2/en not_active Ceased
-
2006
- 2006-04-04 IL IL174762A patent/IL174762A/en not_active IP Right Cessation
- 2006-05-09 NO NO20062088A patent/NO335735B1/no not_active IP Right Cessation
-
2007
- 2007-03-30 HK HK07103420.7A patent/HK1096293A1/xx not_active IP Right Cessation
-
2011
- 2011-05-26 US US13/116,620 patent/US20110229571A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2362561C2 (ru) | 2009-07-27 |
CA2541867C (en) | 2012-06-12 |
AU2004283047B2 (en) | 2009-09-17 |
IL174762A0 (en) | 2006-08-20 |
RU2006115796A (ru) | 2007-11-27 |
WO2005039639A2 (en) | 2005-05-06 |
KR101137084B1 (ko) | 2012-04-24 |
UA83077C2 (ru) | 2008-06-10 |
WO2005039639B1 (en) | 2005-09-22 |
NO20062088L (no) | 2006-07-07 |
ES2304624T3 (es) | 2008-10-16 |
ATE390148T1 (de) | 2008-04-15 |
JP4829115B2 (ja) | 2011-12-07 |
JP2007508276A (ja) | 2007-04-05 |
CN1859924A (zh) | 2006-11-08 |
EP1673107B1 (en) | 2008-03-26 |
DE602004012763D1 (de) | 2008-05-08 |
BRPI0415198A (pt) | 2006-12-05 |
CA2541867A1 (en) | 2005-05-06 |
US20050143435A1 (en) | 2005-06-30 |
KR20060117912A (ko) | 2006-11-17 |
AU2004283047A1 (en) | 2005-05-06 |
MXPA06004029A (es) | 2006-06-28 |
US20110229571A1 (en) | 2011-09-22 |
NO335735B1 (no) | 2015-02-02 |
ZA200601804B (en) | 2007-05-30 |
WO2005039639A3 (en) | 2005-08-11 |
EP1673107A2 (en) | 2006-06-28 |
DE602004012763T2 (de) | 2009-05-07 |
IL174762A (en) | 2010-11-30 |
PL1673107T3 (pl) | 2008-06-30 |
CN100453117C (zh) | 2009-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL174762A0 (en) | Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker | |
TN2009000111A1 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
WO2007111864A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
EP1773330A4 (en) | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | |
TW200605882A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
TW200607798A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
WO2004100875A3 (en) | Benzimidazoles, compositions containing such compounds and methods of use | |
SG165314A1 (en) | Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists | |
EP1590336A4 (en) | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | |
EP2101781A4 (en) | METHOD FOR TREATING OR PREVENTING SYMPTOMS OF HORMONEY CHANGES | |
WO2007106721A3 (en) | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | |
TW200745031A (en) | Acyl indoles, compositions containing such compounds and methods of use | |
EP1942905A4 (en) | NICOTINIC ACID RECEPTOR AGONISTS, COMPOSITIONS CONTAINING THESE COMPOUNDS, AND METHODS OF TREATMENT | |
EP1824812A4 (en) | AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES | |
EP1874301A4 (en) | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SAME, AND METHODS OF TREATMENT | |
IL188329A0 (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
GEP20084492B (en) | New 4-benzylidene-piperidin derivatives | |
WO2007131219A3 (en) | Cannabinoid receptor antagonists/inverse agonists | |
EA200801369A1 (ru) | Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа | |
EP1549655A4 (en) | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS | |
MX2007004461A (es) | Composiciones farmaceuticas a base de antagonistas de nk2 para uso pediatrico. | |
WO2008042800A3 (en) | Human epo receptor agonists, compositions, methods and uses for preventing or treating glucose intolerance related conditions | |
WO2007062837A3 (en) | Use of a 5-ht4 agonist for the treatment of irritable bowel syndrome characterized by mixed or alternating bowel habits | |
WO2004000219A3 (en) | Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof | |
GB0004708D0 (en) | Restricting reinstatement of drug use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20171007 |